Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 58

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 8
Chunk 58
---
 Cancer
    Vaccines 
    $(1,298) 
    $(2,160) 
    $(5,195) 
    $(5,628)
  
    CAR-T
    Therapeutics 
     (973) 
     (1,145) 
     (3,074) 
     (4,115)
  
    Other 
     (9) 
     (10) 
     (37) 
     (42)
  
    Total 
    $(2,280) 
    $(3,315) 
    $(8,306) 
    $(9,785)
  
    Net
    loss 
    $(2,280) 
    $(3,315) 
    $(8,306) 
    $(9,785)

    Total
    operating costs and expenses 
    $2,436  
    $3,592  
    $8,825  
    $10,668 
  
    Less
    non-cash stock-based compensation 
     (855) 
     (1,179) 
     (2,899) 
     (3,699)
  
    Operating
    costs and expenses excluding non-cash stock-based compensation 
    $1,581  
    $2,413  
    $5,926  
    $6,969 

    Operating
    costs and expenses excluding non-cash stock-based compensation: 

    Cancer
    Vaccines 
    $884  
    $1,614  
    $3,714  
    $3,988 
  
    CAR-T
    Therapeutics 
     689  
     789  
     2,180  
     2,943 
  
    Other 
     8  
     10  
     32  
     38 
  
    Total 
    $1,581  
    $2,413  
    $5,926  
    $6,969 
  
    Operating costs and expenses excluding non-cash stock-based compensation 
    $1,581  
    $2,413  
    $5,926  
    $6,969 

    July
    31,  2025  
    October
    31,  2024 
  
    Total
    assets: 

    Cancer
    Vaccines 
    $9,842  
    $12